CN104306735A - Tibetan medicine for treating haemorrhoids - Google Patents
Tibetan medicine for treating haemorrhoids Download PDFInfo
- Publication number
- CN104306735A CN104306735A CN201410576017.1A CN201410576017A CN104306735A CN 104306735 A CN104306735 A CN 104306735A CN 201410576017 A CN201410576017 A CN 201410576017A CN 104306735 A CN104306735 A CN 104306735A
- Authority
- CN
- China
- Prior art keywords
- herba
- tibetan medicine
- group
- powder
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Tibetan medicine for treating haemorrhoids. The medicine is prepared from an active ingredient or an active ingredient and pharmaceutically acceptable auxiliaries, wherein the active ingredient is prepared from dendrobe, sinopodophyllum hexandrum, sabina wallichiana, radix et rhizoma rubiae, cremanthodium reniforme, borax, lac, whin, procumbent speedwell, umbellate rockjasmine herb and myricaria germanica according to a certain weight proportion. The Tibetan medicine can be produced into an arbitrary common internally taken preparation, has the effects of killing parasite, diminishing inflammation and activating blood circulation to remove stasis, and is used for treating haemorrhoids, slight pain, pricking, causalgia, swelling pain, bleeding itching of anus and skin around the anus, defecate haemorrhage, perianal pain and the like.
Description
Technical field
The present invention relates to a kind of Tibetan medicine for the treatment of hemorrhoid, belong to Tibetan medicine field.
Background technology
Hemorrhoid are commonly encountered diseases clinically, frequently-occurring disease, with hemorrhage, deviate from, pain etc. is for cardinal symptom.Along with living standard improves, activity reduces, and hemorrhoid patients gets more and more.Therapeutic Method is a lot, but due to anal canal and skin around the rectum paraesthesia acumen, comparatively responsive to pain.A lot of scholar trends towards for the treatment of hemorrhoid at present: need not treat asymptomatic hemorrhoid, to Symptomatic hemorrhoid according to state of an illness system of selection, mainly contains operation and the large class of non-operative treatment two.
Although the medicine of current treatment hemorrhoid is a lot, curative effect still can not be satisfactory.Therefore, there is tight demand to the Tibetan medicinal preparation that curative effect better treats hemorrhoid in people.
Up to now, any report about Tibetan medicinal composition of the present invention and preparation method thereof is not also found.The present inventor through repeatedly studying, and by the checking repeatedly of animal and clinical trial, finally have found Tibetan medicine oral drugs of the treatment hemorrhoid of better curative effect and preparation method thereof, thus completes the present invention.
Summary of the invention
The object of the invention is just to provide a kind of Tibetan medicine of more effectively treating hemorrhoid.
The present invention is a kind of Tibetan medicine, be be made up of active component or be made up of active component and pharmaceutically acceptable adjuvant, wherein said active component is made up of following bulk drugs: Herba Dendrobii, Chinese podophyllum root, Yunnan-Tibet square bar cypress, ZANGQIANCAO, the chrysanthemum that hangs one's head, Borax, Lacca, Herba Oxytropis Kansuensis, Herba veronicae, Herba Androsaces Umbellatae (Herba Androsaces Coccineae), Cacumen Myricariae Germanicae.
It has selected Herba Dendrobii, Chinese podophyllum root, Yunnan-Tibet square bar cypress, ZANGQIANCAO, the chrysanthemum that hangs one's head, Borax, Lacca, Herba Oxytropis Kansuensis, Herba veronicae, Herba Androsaces Umbellatae (Herba Androsaces Coccineae), Cacumen Myricariae Germanicae carry out combining as crude drug, and wherein (1) Herba Dendrobii is the stem of orchid Dendrobium nobile Dendrobiun nobile Lindl..There is effect of emesis.For dyspepsia, the fever that Baconic's disease causes, hemorrhoid etc.(2) Chinese podophyllum root is fruit, the root welding technology of Berberidaceae plant Chinese podophyllum root Sinopodophyllum hexandrum (Royle) Ying.There is regulating menstruation and activating blood, prevent miscarriage, detumescence, effect of pain relieving.For hysteropathy, menoxenia, amenorrhea, placental retention, endometritis, lumbago ， Xian, impetigo, splenomegaly, the diseases such as hemorrhoid.(3) square bar cypress in Yunnan-Tibet is the fruit of Cupressaceae plant Yunnan-Tibet square bar cypress Sabina wallichiana (Hook.f.et Thoms.) Kom..There is the red bar of convergence, more wound, effect of yellow fluid reducing.Sick for red bar, hemorrhoid, the diseases such as grasserie.(4) ZANGQIANCAO is Maguireothamnus speciosus light stem Radix Rubiae Rubia wallichiana Decne. and Tibet Radix Rubiae R.tibetica Hook.f. and the dry root and rhizome belonging to several plants together.There is effect of clearing away heat and cooling blood.For disorders of blood, diffusion is got mildewed in warm conditions, and lung kidney-heat is evil, intestine and small intestine heat.(5) chrysanthemum that hangs one's head is the dry inflorescence of feverfew Herba Cremanthodii linearis Cremanthodium lineare Maxim..There is effect of heat clearing away, detumescence, pain relieving.For the pain that rheumatism causes, infectious fever, heat in blood, carbuncle, furuncle, hot anthrax.(6) Borax is that borate family Borax race mineral tincal is through refining crystallization.Have heat-clearing and toxic substances removing, antiinflammatory is anticorrosion, effect of blood circulation promoting and blood stasis dispelling.For laryngopharynx swelling and pain, arteriosclerosis, menstruation impatency, various skin infection, blood stasis is not changed.Ulcer, abscess are rinsed in external.(7) Lacca is that the female body of Lacciferidae animal lac insect Laccifer lacca Kerr. parasitizes pulse family wingceltis and belongs on the trunk that DalbergiaL.f. and Sterculiaceae Eriolaena Eriolaenea DC. etc. are main various plants, secreted colloid.There is sterilization, hemostasis, effect of blood circulation promoting and blood stasis dispelling.For blood consumptive disease heat, toxic swelling malignant boil, blood stasis is not changed.(8) Herba Oxytropis Kansuensis is the dry herb of leguminous plant Herba Oxytropis falcatae Oxytropis falcata Bunge and Herba Oxytropis chiliophyllae O.chiliophylla Royle.Have heat-clearing and toxic substances removing, granulation promoting heals skin ulcer, effect of hesitant pulse hemostasis, relieving constipation.Be used for the treatment of epidemic disease, toxonosis, grasserie, constipation, anthrax; External application is controlled furuncle and is swollen and ache.(9) Herba veronicae is the dry herb of goatweed Herba Veronicae ciliatae Veronica ciliata Fisch..There is heat clearing away, more skin ulcer, granulation promoting, effect of hemostasis.For furuncle, wound, inflammation.(10) Herba Androsaces Umbellatae (Herba Androsaces Coccineae) is the dried floral of Ofthe Primulaceae stone Androsace henryi Oliv Androsace integra (Maxim.) Hand.-Mazz..There is heat clearing away, yellow fluid reducing, draw the effect of rushing down ascites.For anthrax, grasserie, heart disease edema, hot edema.(11) Cacumen Myricariae Germanicae is Tamaricaceae Cacumen Myricariae Germanicae Myricaria germanica (L.) Desv. and the dry twig belonging to several plants together.There is heat-clearing and toxic substances removing, disperse effect of rash.For measles without adequate eruption, laryngopharynx swelling and pain, nosotoxicosis, grasserie, heat in blood is sick, and pestilence epidemic disease, internal organs are scorchingly hot.These crude drug are combinationally used and makes each crude drug effect produce synergism, thus effectively can treat hemorrhoid.
The consumption of Tibetan medicine active component of the present invention is also through inventor and gropes in a large number to sum up and draw, each crude drug consumption for all to have good therapeutic effect within the scope of following concrete weight proportion:
Herba Dendrobii 25 ~ 75g, Chinese podophyllum root 20 ~ 60g, Yunnan-Tibet square bar cypress 20 ~ 60g, ZANGQIANCAO 15 ~ 45g, the chrysanthemum 15 ~ 45g that hangs one's head, Borax 10 ~ 30g, Lacca 7.5 ~ 22.5g, Herba Oxytropis Kansuensis 15 ~ 45g, Herba veronicae 20 ~ 60g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 15 ~ 45g, Cacumen Myricariae Germanicae 10 ~ 30g.
Be preferably: Herba Dendrobii 40 ~ 60g, Chinese podophyllum root 32 ~ 48g, Yunnan-Tibet square bar cypress 32 ~ 48g, ZANGQIANCAO 24 ~ 36g, the chrysanthemum 24 ~ 36g that hangs one's head, Borax 16 ~ 24g, Lacca 12 ~ 18g, Herba Oxytropis Kansuensis 24 ~ 36g, Herba veronicae 32 ~ 48g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 24 ~ 36g, Cacumen Myricariae Germanicae 16 ~ 24g.
More preferably: Herba Dendrobii 50g, Chinese podophyllum root 40g, Yunnan-Tibet square bar cypress 40g, ZANGQIANCAO 30g, the chrysanthemum 30g that hangs one's head, Borax 20g, Lacca 15g, Herba Oxytropis Kansuensis 30g, Herba veronicae 40g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 30g, Cacumen Myricariae Germanicae 20g.
The preparation of Tibetan medicine active component of the present invention can be pulverized by the crude drug convection drying of above-mentioned consumption to make; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (see " pharmaceutics of Chinese drugs " 73rd ~ 74 pages of Cao Chunlin chief editor, Science and Technology of Shanghai publishing house publishes in November, 1986) to obtain.
The active component of Tibetan medicine of the present invention can add various customary adjuvant required when preparing different dosage form, as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (see Cao Chunlin chief editor " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house in November, 1986 publishes) be prepared into any one and commonly use peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has parasite killing, antiinflammatory, effect of blood circulation promoting and blood stasis dispelling.For hemorrhoid, mild pain, twinge, causalgia, distending pain, anus and the hemorrhage pruritus of crissum skin, hemorrhage and crissum pain etc. during stool.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1 ~ 1.5g, 2 ~ 3 times on the one.
[detailed description of the invention]
Carry out the preparation method setting forth Tibetan medicine of the present invention further by the following examples.
The preparation of [embodiment 1] Tibetan medicine powder of the present invention:
Take Herba Dendrobii 50g, Chinese podophyllum root 40g, Yunnan-Tibet square bar cypress 40g, ZANGQIANCAO 30g, the chrysanthemum 30g that hangs one's head, Borax 20g, Lacca 15g, Herba Oxytropis Kansuensis 30g, Herba veronicae 40g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 30g, Cacumen Myricariae Germanicae 20g, jointly fine powder is ground into after mixing, mixing, subpackage, obtains powder.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention:
Take Herba Dendrobii 25g, Chinese podophyllum root 20g, Yunnan-Tibet square bar cypress 20g, ZANGQIANCAO 15g, the chrysanthemum 15g that hangs one's head, Borax 10g, Lacca 7.5g, Herba Oxytropis Kansuensis 15g, Herba veronicae 20g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 15g, Cacumen Myricariae Germanicae 10g, jointly fine powder is ground into after mixing, mixing, with water pill, dry below 60 DEG C, polishing, packaging, obtains pill.
The preparation of [embodiment 3] Tibetan medicine granule of the present invention:
Take Herba Dendrobii 75g, Chinese podophyllum root 60g, Yunnan-Tibet square bar cypress 60g, ZANGQIANCAO 45g, the chrysanthemum 45g that hangs one's head, Borax 30g, Lacca 22.5g, Herba Oxytropis Kansuensis 45g, Herba veronicae 60g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 45g, Cacumen Myricariae Germanicae 30g, jointly fine powder is ground into after mixing, mixing, add adjuvant and make granule, dry below 60 DEG C, granulate, subpackage, obtains granule.
The preparation of [embodiment 4] Tibetan medicine capsule of the present invention:
Take Herba Dendrobii 40g, Chinese podophyllum root 32g, Yunnan-Tibet square bar cypress 32g, ZANGQIANCAO 24g, the chrysanthemum 24g that hangs one's head, Borax 16g, Lacca 12g, Herba Oxytropis Kansuensis 24g, Herba veronicae 32g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 24g, Cacumen Myricariae Germanicae 16g, jointly fine powder is ground into after mixing, mixing, loads gelatine capsule, obtains capsule.
The preparation of [embodiment 5] Tibetan medicine tablet of the present invention:
Take Herba Dendrobii 60g, Chinese podophyllum root 48g, Yunnan-Tibet square bar cypress 48g, ZANGQIANCAO 36g, the chrysanthemum 36g that hangs one's head, Borax 24g, Lacca 18g, Herba Oxytropis Kansuensis 36g, Herba veronicae 48g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 36g, Cacumen Myricariae Germanicae 24g, jointly fine powder is ground into after mixing, mixing, add adjuvant and make granule, dry below 60 DEG C, granulate, tabletting, obtains tablet.
Set forth the beneficial effect of Tibetan medicine of the present invention further below by way of test example, these test examples include pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine embodiment 1 powder of the present invention.
The test such as hemostasis, analgesic activity of [test example 1] Tibetan medicine embodiment 1 powder of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1 powder is trial drug; Aspirin tablet, lot number: 20100809, is produced by Changbaishan Pharmacy Co., Ltd; Yunnan Baiyao Capsule, lot number: 20100312, is produced by Yunnan Baiyao Group Wuxi Medicine Co., Ltd.; Reagent and instrument PT measure test kit (lot number: 20100806), APTT measures test kit (lot number: 20100204) provide by French STAGO-R company; Adenosine diphosphate (ADP) disodium (ADP, Shanghai Bai Ao Bioisystech Co., Ltd, lot number: 20100713); Glacial acetic acid; Filter paper; Stopwatch; Microscope slide; Rat calcitonin-gene-related peptide (CGRP) ELISA kit, purchased from Xi Tang bio tech ltd, Shanghai; France STAGO-R Automatic coagulometer; Chrono-log 560vs platelet aggregation instrument.Kunming mouse, SD rat, provide by Lanzhou Experimental Animal Center.
Experimental technique and result: 1, the impact of, clotting time hemorrhage on SD rat: get SD rat 50, be divided into 5 groups at random, often organize 10, i.e. blank group, to isometric(al) distilled water; Positive controls, to Yunnan Baiyao Capsule 0.5g/kg.d
-l; Tibetan medicine embodiment 1 powder (6g, 3g, 1.5g crude drug/kg.d of the present invention
-l) high, medium and low dosage group.Sub-cage rearing, the equal gastric infusion of each group, 1 time/d, continuous 7d.12h after last administration, fixedly cuts tail 5cm by rat, clocks immediately, sucks drop of blood every 30s filter paper, is the bleeding time to no longer hemorrhage.Separately get SD rat 50, ditto, 12h after last administration, fixes rat, plucks side eyeball and gets blood, and bleed for each one in the two ends of microscope slide, drop of blood diameter is about 5mm, clocks immediately with stopwatch for grouping and administering mode.Stir 1 time gently every the clean pin of 30s inwards from drop of blood edge, and observation is provoked with or without the blood streak.To only provoking the blood streak from blood sampling, be clotting time between institute lasts.Another bleeds for last reinspection, record clotting time.The results are shown in Table 1.
Table 1 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) in rat blood coagulation, bleeding time
Group Animals number dosage (g/kg) clotting time (s) bleeding time (s)
Blank group 10 124.48 ± 14.38
★ ★ ▲ ▲429.3 ± 71.36
★ ★ ▲ ▲
Positive controls 10 0.5 86.3 ± 11.37
*155.4 ± 58.12
*
Low dose group 10 1.5 89.7 ± 12.58
*213.1 ± 87.42
*
Middle dosage group 10 3 67.6 ± 11.36
* ▲149.3 ± 48.63
*
High dose group 10 6 43.9 ± 11.14
* ★ ★ ▲ ▲106.5 ± 23.79
* ▲
Illustrate: compare with blank group:
*p<0.01; Compare with positive controls:
★ ★p<0.01,
★p<0.05; Compare with low dose group:
▲ ▲p<0.01,
▲p<0.05.
As seen from Table 1: during the clotting time affecting Tibetan medicine embodiment 1 powder of the present invention heavy dose group in the blood coagulation of SD rat, bleeding time is significantly shorter than, small dose group, positive controls and blank group (P<0.01), low dose group and positive controls there was no significant difference (P>0.05); The bleeding time of Tibetan medicine embodiment 1 powder high dose group of the present invention is significantly shorter than low dose group and blank group (P<0.05), with middle dosage group and positive controls there was no significant difference (P>0.05).
2, Tibetan medicine embodiment 1 powder of the present invention is on the impact of PT, APTT of SD rat: get SD rat 50, and grouping and administering mode are with under 1.12h after last administration, with 10% chloral hydrate (0.4 ~ 0.6ml/100g) intraperitoneal injection of anesthesia rat, open abdominal cavity, from abdominal aortic blood 2.7mL, put in vitro (ratio of blood and sodium citrate is 9: 1) that be added with 3.8% liquor sodii citratis, with 3000rmin after mixing
-1centrifugal 10min, obtains Platelet poor (PPP) blood plasma, then adopts application of automated coagulation analyzer to measure PT, APTT.The results are shown in Table 2.
Table 2 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of P of Rats T, APTT
Group Animals number dosage (g/kg) PT/s APTT/s
Blank group 10
?22.85 ± 2.38
▲ ▲24.73 ± 2.25
▲
Positive controls 10 0.5 16.35 ± 1.35
*20.48 ± 1.23
*
Low dose group 10 1.5 16.49 ± 1.27
* ★21.68 ± 2.35
* ★
Middle dosage group 10 3 16.38 ± 1.52
* ★18.93 ± 1.54
* ▲
High dose group 10 6 16.15 ± 1.36
* ★17.56 ± 1.46
* ★
Illustrate: compare with blank group:
*p<0.01; With YUNNAN BAIYAO group:
★p>0.05; Compare with small dose group:
▲p<0.05.
As seen from Table 2: blank group (P<0.01) is all significantly shorter than, with positive controls there was no significant difference (P>0.05) to PT, APTT time affecting each dosage group of Tibetan medicine embodiment 1 powder of the present invention of PT, APTT of SD rat.
3, Tibetan medicine embodiment 1 powder of the present invention is on the impact of the platelet aggregation rate of SD rat: get SD rat 50, and grouping, administering mode and blood sampling are all with under 2.With 1000rmin after mixing
-1centrifugal 15min, gets upper strata platelet rich plasma (PRP) 450 μ l, and remainder continues with 3000rmin
-1centrifugal 10min, be separated Platelet poor (PPP) blood plasma, with platelet poor plasma (PPP) for control tube zeroing, in platelet rich plasma (PRP), add derivant 3.33 μm of ol/LADP 40 μ l, measure platelet aggregation degree by turbidimetry in blood pool instrument.The results are shown in Table 3.
Table 3 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of rat platelet aggregation rate
Group Animals number dosage (g/kg) ADP (maximum agglutination rate)
Blank group 10 47.8 ± 10.8
Positive controls 10 0.5 79.4 ± 18.7
*
Low dose group 10 1.5 63.8 ± 13.8
* ★
Middle dosage group 10 3 81.7 ± 11.8
* ★ ▲ ?
High dose group 10 6 62.9 ± 12.7
* ★
Illustrate: compare with blank group:
*p<0.05,
*p<0.01; Compare with positive controls:
★p>0.05; Compare with low dose group:
▲p<0.05.
As seen from Table 3: on the platelet aggregation rate affecting dosage group in Tibetan medicine embodiment 1 powder of the present invention of the platelet aggregation rate of SD rat apparently higher than high and low dose group and blank group (P<0.05), with positive controls there was no significant difference (P >0. 05).
4, Tibetan medicine embodiment 1 powder of the present invention affects hot plate method in mice analgesic: because the male mice scrotum that is heated touches hot plate, can occur spurious results, so experiment adopts female mice.500ml beaker, to (55.0 ± 0.5) DEG C, is put into wherein by regulation thermostat water temperature, makes beaker bottom contact the water surface.Get Kunming kind female mice 1 at every turn, put into beaker.Record is from putting into beaker to occurring licking rear foot required time (s), as the pain threshold of this Mus.Allly lick the metapedes time and be less than 5s or be greater than 30s or leaper gives it up.Interval 1h, its normal pain threshold of replication, gets two subnormal threshold of pain meansigma methodss, and as the Basic Pain Threshold value before the administration of this Mus, it is qualified for being no more than 30s with meansigma methods.Qualified mice is divided into 5 groups at random, and often organize 10, i.e. blank group, to isometric(al) distilled water; Positive controls, to aspirin tablet 0.6g/kg.d
-l; Tibetan medicine embodiment 1 powder (6g, 3g, 1.5g crude drug/kg.d of the present invention
-l) high, medium and low dosage group.Sub-cage rearing, the equal gastric infusion of each group, 1 time/d, continuous 7d.After administration in the 7th day, 6h respectively measures the pain threshold of mice.Mice is taken off rapidly after occurring licking foot reaction, in order to avoid scald.If 60s is still reactionless, take out immediately, its threshold of pain is pressed 60s and is calculated.Occur that the time difference (pain threshold) of licking foot reaction is for observation index, calculates medicine analgesic percentage rate with mice.The results are shown in Table 4.
Table 4 Tibetan medicine embodiment 1 of the present invention powder is to hot plate method in mice analgesic effect (x ± s, n=10)
(s) rate elongation (%) after (s) 6h before Group Animals number dosage (g/kg) medication
Blank group 10 12.78 ± 4.32 12.27 ± 4.24
★ ▲ ▲
Positive controls 10 0.6 11.76 ± 4.31 21.89 ± 5.43
*84.28
Low dose group 10 1.5 11.98 ± 3.15 20.23 ± 4.47
*79.32
Middle dosage group 10 3 11.82 ± 4.26 21.29 ± 4.16
*86.12
High dose group 10 6 11.54 ± 3.52 22.87 ± 5.44
*98.72
Illustrate: compare with blank group:
*p<0.01; Compare with positive controls:
★ ★p<0.01; Compare with low dose group:
▲ ▲p<0.01.
As seen from Table 4: each dosage group of Tibetan medicine embodiment 1 powder of the present invention is affected on hot plate method in mice analgesic and compares with blank group, hot plate method in mice pain threshold can be significantly improved, all have significant difference (P<0.01); Positive controls is compared with each dosage group of Tibetan medicine embodiment 1 powder of the present invention, and no significant difference (P>0.05), points out it to improve hot plate method in mice pain threshold effect suitable; Tibetan medicine embodiment 1 powder of the present invention each dosage group analgesia rate and dosage linear, during high dose is better than, low dose group; In positive controls analgesia rate and Tibetan medicine embodiment 1 powder of the present invention, dosage group is suitable.
5, Tibetan medicine embodiment 1 powder of the present invention affects mice acetic acid writhing test analgesic: laboratory animal, grouping, administration are with under 4.Sub-cage rearing, the equal gastric infusion of each group, 1 time/d, continuous 7d.6h after administration in the 7th day, with the acetum of 0.6%, by the dosage of 0.1ml/10g, lumbar injection.To give after acetic acid in 15min, each test mice occurs that writhing (abdominal part indent, stretch hind leg, buttocks raises) number of times is observation index, calculates writhing response frequency.The results are shown in Table 5.
Table 5 Tibetan medicine embodiment 1 of the present invention powder is to mice method of acetic acid analgesic effect (x ± s, n=10)
Writhing number of times in Group Animals number dosage (g/kg) 15min
Blank group 10 28.69 ± 7.62
★ ★ ▲ ▲
Positive controls 10 0.6 12.97 ± 6.18
*
Low dose group 10 1.5 15.86 ± 6.56
*
Middle dosage group 10 3 14.43 ± 5.68
*
High dose group 10 6 7.49 ± 3.45
* ▲
Illustrate: compare with blank group:
*p<0.01; Compare with positive controls:
★ ★p<0.01; Compare with low dose group:
▲ ▲p<0.01,
▲p<0.05.
As seen from Table 5: each dosage group of Tibetan medicine embodiment 1 powder of the present invention is affected on mice acetic acid writhing test analgesic and compares with blank group, significantly can reduce mouse writhing frequency (P<0.01); Positive controls is compared with each dosage group of Tibetan medicine embodiment 1 powder of the present invention, and no significant difference (P>0.05), points out it to reduce mouse writhing frequency effect suitable; Tibetan medicine embodiment 1 powder of the present invention each dosage group reduce writhing frequency and dosage linear, during high dose is better than, low dose group.
6, Tibetan medicine embodiment 1 powder of the present invention is to rat plasma CGRP level determination result: get SD rat 50, and grouping and administering mode are with under 1.12h after last administration, with 10% chloral hydrate (0.4 ~ 0.6ml/100g) anesthetized rat, from abdominal aortic blood 5ml, inject the test tube of EDTA-2Na (1g/L) and aprotinin (50mU/L), shake up, 4 DEG C, the centrifugal 10min of 3000r/min isolates blood plasma 1 part, put-70 DEG C of cryogenic refrigerators to preserve, CGRP value to be measured.The results are shown in Table 6.
Table 6 Tibetan medicine embodiment 1 of the present invention powder is on the impact (x ± s, n=10) of rat CGRP level
Group Animals number dosage (g/kg) CGRP
Blank group 10 342.93 ± 103.46
Positive controls 10 0.6 427.68 ± 183.53
Low dose group 10 1.5 413.69 ± 124.14
Middle dosage group 10 3 522.79 ± 117.31
*
High dose group 10 6 629.96 ± 131.42
* ▲ ?
Illustrate: compare with blank group:
*p<0.01; Compare with positive controls:
★ ★p<0.01; Compare with low dose group:
▲p<0.05.
As seen from Table 6: pharmaceutical intervention is carried out after 7 days to rat plasma CGRP level determination result 5 groups of SD rats, its Plasma level of CGRP result shows: compared with blank group, Tibetan medicine embodiment 1 powder high dose group of the present invention has dosage group in remarkable rising (P<0.01), Tibetan medicine embodiment 1 powder of the present invention to be also increased significantly (P<0.05); Compared with Tibetan medicine embodiment 1 powder small dose group of the present invention, Tibetan medicine embodiment 1 powder high dose group of the present invention has remarkable reduction (P<0.05), positive controls and its no significant difference (P>0.05).
The clinical observation on the therapeutic effect of [test example 2] Tibetan medicine embodiment 1 powder treatment of the present invention mixed hemorrhoid:
Physical data: totally 120 examples observe patient, are divided into two groups at random by digital method, is respectively 60 examples.
Diagnostic criteria: formulate with reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect " mixed hemorrhoid diagnosis basis.1. to have blood in stool and podex swells thing, rectal tenesmus, foreign body sensation or pain can be had.2. can with merocrine secretion's thing or pruritus.3. in anal canal there is swollen thing (also can be superfluous skin under tooth trace) in the upper and lower same orientation of tooth trace.
Therapeutic Method: matched group: adopt Fructus Cannabis Bolus treatment, oral, a 9g, 2 times on the one.It within 15th, is a course for the treatment of.Treatment group: adopt Tibetan medicine embodiment 1 powder of the present invention, oral, a 1.5g, 3 times on the one.It within 15th, is a course for the treatment of.
Clinical efficacy evaluation criteria: formulate with reference to State Administration of Traditional Chinese Medicine's " Chinese medical disease Standardization of diagnosis and curative effect " mixed hemorrhoid efficacy assessment standard.Cure: transference cure, hemorrhoid disappear.Take a turn for the better: symptom is improved, and hemorrhoid reduce.Do not heal: symptom, sign are all unchanged.Healing adds improvement and adds up to total effective rate.
Clinical observation result is in table 7.
Table 7 liang group Clinical efficacy comparison (example, %)
Group number of cases cures the more total effective rate that takes a turn for the better not
Treatment group 60 51 54 93.33
Matched group 60 39 13 8 86.67
Clinical observation result shows: Tibetan medicine embodiment 1 powder treatment mixed hemorrhoid determined curative effect of the present invention, clinic is promoted the use of, and has certain application prospect.
In the preparation of conventional oral solid formulation, the preparation of powder be in other conventional oral solid formulation preparation process before process portion, the test example of powder demonstrates has good effect in treatment hemorrhoid, also just describes the pill in conventional oral solid formulation, granule, capsule, tablet also have same effect; Namely the above-mentioned embodiment 1-5 enumerated has same effect.Illustrate that Tibetan medicine of the present invention has good effect in treatment hemorrhoid.
Claims (5)
1. treat the Tibetan medicine of hemorrhoid for one kind, it is characterized in that it is made up of active component or is made up of active component and pharmaceutically acceptable adjuvant, wherein said active component is made up of the crude drug of following concrete weight proportion: Herba Dendrobii 25 ~ 75g, Chinese podophyllum root 20 ~ 60g, Yunnan-Tibet square bar cypress 20 ~ 60g, ZANGQIANCAO 15 ~ 45g, the chrysanthemum 15 ~ 45g that hangs one's head, Borax 10 ~ 30g, Lacca 7.5 ~ 22.5g, Herba Oxytropis Kansuensis 15 ~ 45g, Herba veronicae 20 ~ 60g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 15 ~ 45g, Cacumen Myricariae Germanicae 10 ~ 30g.
2. Tibetan medicine according to claim 1, wherein said active component is made up of the crude drug of following concrete weight proportion: Herba Dendrobii 40 ~ 60g, Chinese podophyllum root 32 ~ 48g, Yunnan-Tibet square bar cypress 32 ~ 48g, ZANGQIANCAO 24 ~ 36g, the chrysanthemum 24 ~ 36g that hangs one's head, Borax 16 ~ 24g, Lacca 12 ~ 18g, Herba Oxytropis Kansuensis 24 ~ 36g, Herba veronicae 32 ~ 48g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 24 ~ 36g, Cacumen Myricariae Germanicae 16 ~ 24g.
3. Tibetan medicine according to claim 2, wherein said active component is made up of the crude drug of following concrete weight: Herba Dendrobii 50g, Chinese podophyllum root 40g, Yunnan-Tibet square bar cypress 40g, ZANGQIANCAO 30g, the chrysanthemum 30g that hangs one's head, Borax 20g, Lacca 15g, Herba Oxytropis Kansuensis 30g, Herba veronicae 40g, Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 30g, Cacumen Myricariae Germanicae 20g.
4., according to any one Tibetan medicine described in claim 1-3, it is peroral dosage form.
5. Tibetan medicine according to claim 4, it is powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410576017.1A CN104306735A (en) | 2014-10-26 | 2014-10-26 | Tibetan medicine for treating haemorrhoids |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410576017.1A CN104306735A (en) | 2014-10-26 | 2014-10-26 | Tibetan medicine for treating haemorrhoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306735A true CN104306735A (en) | 2015-01-28 |
Family
ID=52362144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410576017.1A Pending CN104306735A (en) | 2014-10-26 | 2014-10-26 | Tibetan medicine for treating haemorrhoids |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306735A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836186A (en) * | 2012-09-17 | 2012-12-26 | 措尼 | Tibetan medicine for treating haemorrhoids and preparation method thereof |
| CN103316166A (en) * | 2013-07-17 | 2013-09-25 | 宋永心 | Tibetan medicine for treating hemorrhoids and preparation method thereof |
-
2014
- 2014-10-26 CN CN201410576017.1A patent/CN104306735A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836186A (en) * | 2012-09-17 | 2012-12-26 | 措尼 | Tibetan medicine for treating haemorrhoids and preparation method thereof |
| CN103316166A (en) * | 2013-07-17 | 2013-09-25 | 宋永心 | Tibetan medicine for treating hemorrhoids and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 贠田等: "二十五味鬼臼丸体外的抑菌作用", 《华西药学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038975A (en) | Chinese medicinal herbal plant liquid cotton gauze sanitary towel | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN105748543B (en) | A Chinese medicinal composition for treating rheumatic diseases, and its preparation method | |
| CN101703684B (en) | Medicament for treating allergic purpura and preparation method thereof | |
| CN101342356B (en) | Traditional Chinese medicine preparation for congestion retardarce, haemal tube obstruction and preparation method thereof | |
| CN102836186B (en) | Tibetan medicine for treating haemorrhoids and preparation method thereof | |
| CN102772712B (en) | Traditional Chinese medicine composition for treating heat-toxicity, flourishing and blood stasis type diabetic foot | |
| CN104906465A (en) | Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof | |
| CN103316166B (en) | Tibetan medicine for treating hemorrhoids and preparation method thereof | |
| CN109464583B (en) | Anti-inflammatory traditional Chinese medicine composition for livestock and preparation method and application thereof | |
| CN101371905B (en) | Chinese medicine lozenge for treating throat disease | |
| CN104288524A (en) | Method for preparing Tibetan medicine for treating hemorrhoids | |
| CN101450117B (en) | Rheumatism treatment medicine composition, formulation and preparation method | |
| CN103721138A (en) | External traditional Chinese medicinal preparation for treating acne rosacea and preparation method thereof | |
| CN107582633B (en) | External traditional Chinese medicine preparation for treating urticaria and preparation method thereof | |
| CN103585580B (en) | A kind of Chinese medicine preparation for recurrent oral ulceration | |
| CN104306735A (en) | Tibetan medicine for treating haemorrhoids | |
| CN102631426A (en) | Traditional Chinese medicine composition for treating anaphylactoid purpura | |
| CN101884664B (en) | Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof | |
| CN110680856A (en) | Eczema fumigation powder | |
| CN102335304B (en) | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof | |
| CN105233073B (en) | Chinese medicinal enema and preparation method thereof for cooling | |
| CN105194263A (en) | Traditional Chinese medicine composition for treating rheumatic skin itching and preparation method thereof | |
| CN104474469A (en) | Method for preparing electric injury paste preparation | |
| CN104740565A (en) | Traditional Chinese medicine composition for treating cold injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150128 |